$VACC News
Last published 3y ago
- 3y agoVACCBRNSVaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and CancerGlobeNewswireNew Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc
- 3y agoBMYBPTSONCYRNAZ+1Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors RisePR NewswirePALM BEACH, Fla. , Sept. 26, 2023 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid increase in the prevalence
- 3y agoVACCVaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023GlobeNewswireOXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to
- 3y agoVACCVaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to
- 3y agoVACCVaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis BGlobeNewswireMeaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo patients developed a non-detectable HBsAg level, which continued
- 3y agoABUSVACCArbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal AntibodyGlobeNewswireEvaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS)
- 3y agoVACCVaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local TherapyGlobeNewswireOXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel
- 3y agoVACCVaccitech Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel
- 3y agoVACCVaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity ProfileGlobeNewswireVTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human
- 3y agoVACCPharmaron's Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support £151m InvestmentBusiness WireBuilding capacity in Gene Therapy Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) ("Pharmaron") announced today that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the
- 3y agoABUSVACCVaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis BGlobeNewswireCompleted Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg)Results will be
- 3y agoVACCVaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel
- 3y agoVACCVaccitech's VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical LesionsGlobeNewswireVTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs)Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 antigens used in
- 3y agoVACCVaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific OfficerGlobeNewswireDr. Pelletier joins leadership team to continue the advancement of Vaccitech's diverse clinical pipeline and partnerships, bringing more than 15 years' experience in pharmaceuticals and academia in immunology and
- 3y agoVACCVaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune DiseasesGlobeNewswireOXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic
- 4y agoVACCVaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's
- 4y agoVACCVaccitech to Present at Upcoming November Investors ConferencesGlobeNewswireOXFORD, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the
- 4y agoVACCVaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis BGlobeNewswireVTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial. VTP-300 as a monotherapy and in combination with a single
- 4y agoVACCVaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300GlobeNewswireOXFORD, United Kingdom, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today
- 4y agoVACCVaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV PatientsGlobeNewswireOXFORD, United Kingdom, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today
- 4y agoVACCPublication in Cell Shows That Vaccitech's SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel "Vax-Innate" ParadigmGlobeNewswireVaccitech collaborators at NIH's Vaccine Research Center demonstrate that IV administration of SNAPvax in animal models activates two key pathways leading to improved T cell mediated tumor killing in a paradigm referred
- 4y agoVACCVaccitech to Present at Upcoming October Investor & Scientific ConferencesGlobeNewswireOXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chie
- 4y agoVACCVaccitech Promotes Gemma Brown as Chief Financial OfficerGlobeNewswireOXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma
- 4y agoVACCVaccitech to Present at Upcoming September Investors ConferencesGlobeNewswireOXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chi
- 4y agoVACCVaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company's recent corporate developments. Vaccitech is
- 4y agoVACCVaccitech to Present at the William Blair Biotech Focus Conference 2022GlobeNewswireOXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chie
- 4y agoVACCVaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1GlobeNewswireVTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab was administered, with no treatment-related serious adverse events and infrequent transient transaminitis. Meaningful, durable reductions of Hepatitis B sur
- 4y agoVACCVaccitech to Present at the Jefferies Healthcare ConferenceGlobeNewswireOXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chie
- 4y agoABUSVACCArbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B VirusGlobeNewswireTrial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapy WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharma
- 4y agoVACCVaccitech to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireOXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief
- 4y agoVACCVaccitech Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Company's recent corporate developments. Vaccitech is
- 4y agoVACCVaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®GlobeNewswireOXFORD, United Kingdom, April 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that it has been notif
- 4y agoVACCVaccitech Reports Full-Year 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of the Company's recent corporate developments. Vaccitech is
- 4y agoVACCVaccitech to Present at the Barclays Global Healthcare Conference 2022GlobeNewswireOXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chi
- 4y agoVACCCancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy VaccineGlobeNewswireOXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (NASDAQ:VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunoth
- 4y agoVACCVaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics LandscapeGlobeNewswireOXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc ("Vaccitech"), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual
- 4y agoVACCVaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccinesGlobeNewswireComplementary technology platforms, expertise and capabilities provide unique synergistic opportunities. Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvaxTM platform, which has demonstrated unprecedented control
- 4y agoVACCVaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBVGlobeNewswireInterim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the group receiving low-dose nivolumab with the heterologous
- 4y agoVACCVaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare ConferenceGlobeNewswireOXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chie
- 5y agoVACCVaccitech's VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim AnalysesGlobeNewswireInterim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T cells against targeted hepatitis B viral antigens. C
- 5y agoVACCVaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced its financial results for the third quarter, ended September 30, 2021, and provided an overview of the Company's recent corporate developments. Vaccit
- 5y agoVACCVaccitech to Present at the Jefferies London Healthcare ConferenceGlobeNewswireOXFORD, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chie
- 5y agoVACCVaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS CoronavirusGlobeNewswireThe Phase 1 clinical trial was conducted by The King Abdullah International Medical Research Centre (KAIMRC), in the Kingdom of Saudi Arabia (KSA), in partnership with the University of Oxford. Vaccitech retains commercial rights to this vaccine. The
- 5y agoVACCVaccitech Announces Data Presentations at AASLD's Liver Meeting® 2021GlobeNewswireOXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced two poster presentations at AASLD
- 5y agoVACCVaccitech to Present at Upcoming September Investor conferencesGlobeNewswireOXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of inf
- 5y agoVACCVaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of the Company's recent corporate developments. Vaccitech
- 5y agoVACCVaccitech to Present at the William Blair Biotech Focus Conference 2021GlobeNewswireOXFORD, United Kingdom, July 08, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infe
- 5y agoABUSVACCArbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus InfectionGlobeNewswireWARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) and Vaccitech plc (NASDAQ:VACC) today announced that the companies have entered into a clinical trial collaboration agreement to e
- 5y agoVACCVaccitech Reports First Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewswireOXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infe
- 5y agoVACCVaccitech to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewswireOXFORD, United Kingdom, June 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infe